Advocates took to Capitol Hill last week to brief lawmakers and their staff about the implications the recent CMS policy change may have on patient access to treatments.
Last month, CMS announced that it would begin to allow Medicare Advantage plans to implement step therapy as a negotiation tool for drug prices. The announcement was met with concern as various industry stakeholders, such as the Community Oncology Alliance, the American College of Rheumatology (ACR), and the American Society of Clinical Oncology, all spoke out against the change.
Hosted by the Part B Access for Seniors and Physicians (ASP) Coalition, advocates took to Capitol Hill last week to brief lawmakers and their staff about the implications the policy may have on patient access to treatments covered under the Medicare Part B program.
Read more about how seniors may be impacted by the Medicare policy change.
Providing the physician viewpoint of step therapy during the meeting was Angus Worthing, MD, FACP, FACR, a practicing rheumatologist and chair of the ACR’s government affairs committee. “Far too many of my patients with Medicare prescription drug plans have experienced frustrating delays in getting treatment due to step therapy,” he said. “Expanding step therapy to [Medicare Advantage] plans will only add more people to the list of those who will face difficulties assessing the care prescribed by their physician as the best course of care.”
Lawmakers also heard from Katie Roberts, a patient advocate with the Arthritis Foundation. “As an individual with psoriatic arthritis, I am unfortunately all too familiar with how even seemingly brief delays in treatment can make a crucial difference in a patient’s life… Lawmakers must understand that this policy change will do real harm to individuals with chronic diseases by delaying treatment access at a time when it is most critically needed.”
During the briefing, a representative from Xcenda, a policy research and consulting firm, provided an overview of their recent report that analyzed physicians’ prescribing behavior through the Medicare Part B program. The report, titled “Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?” found that “there is no meaningful correlation between drug payment and utilization, challenging the theory that physicians significantly favor drugs with high add-on payments.”
Though many industry groups have spoken out against the policy change, CMS has remained firm in its decision. The policy change will take effect in January 2019.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability
June 20th 2024The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.
British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years
June 18th 2024British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.